New anti-tumor cell therapy strategies are more effective

October 25, 2012

Targeted T-cells can seek out and destroy tumor cells that carry specific antigen markers. Two novel anti-tumor therapies that take advantage of this T-cell response are described in articles published in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The articles are available free on the Human Gene Therapy website.

Richard Morgan and colleagues from the (NCI), National Institutes of Health (NIH), Bethesda, MD, and Duke University Medical Center, Durham, NC, used engineered T-cells to attack glioma stem cells, which are one of the cell types present in glioblastoma, an aggressive and fatal type of brain cancer. There is no curative treatment for glioblastoma, and patients usually live less than two years from diagnosis. In the article "Recognition of Glioma Stem Cells by Genetically Modified T Cells Targeting EGFRvIII and Development of Adoptive Cell Therapy for Glioma," the authors describe how targeting tumor stem cells, in combination with traditional therapies aimed at killing other types of glioma , could improve the effectiveness of treatment and reduce tumor recurrence.

In a related article, Karen Kaluza and coauthors, Mayo Clinic, Rochester, MN, conducted a study using T-cells capable of recognizing two different antigens simultaneously and showed that this dual targeting strategy could be more effective at clearing tumor cells and reducing the risk of "tumor escape" and cancer recurrence. In "Adoptive Transfer of Cytotoxic Targeting Two Different Antigens Limits Antigen Loss and Tumor Escape," the authors conclude that T-cell therapies targeting two or more antigens will have significant added value compared to single-antigen therapies.

"These studies represent important advances in the development of novel treatments for cancer that combine the power of gene transfer and ," says James M. Wilson, MD, PhD, Editor-in-Chief, and Director of the Gene Therapy Program, Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia.

Explore further: New universal platform for cancer immunotherapy developed

Related Stories

New universal platform for cancer immunotherapy developed

March 5, 2012
(Medical Xpress) -- Researchers from the Perelman School of Medicine at the University of Pennsylvania report this month in Cancer Research a universal approach to personalized cancer therapy based on T cells. It is the first ...

Metabolic state of brain cancer stem cells significantly different than the cancer cells they create

September 6, 2011
The metabolic state of glioma stem cells, which give rise to deadly glioblastomas, is significantly different from that of the brain cancer cells to which they give birth, a factor which helps those stem cells avoid treatment ...

How immune cells destroy cancer cells: Researchers elucidate mechanism

January 17, 2012
In the treatment of large tumors, how effective is adoptive T cell therapy in comparison to drug-based cancer treatment? To answer this question, Dr. Kathleen Anders and Professor Thomas Blankenstein of the Max Delbrück ...

Cancer stem cell vaccine in development shows antitumor effect

April 2, 2012
Scientists may have discovered a new paradigm for immunotherapy against cancer by priming antibodies and T cells with cancer stem cells, according to a study published in Cancer Research, a journal of the American Association ...

Recommended for you

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance

July 24, 2017
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells—glioma stem cells—is responsible for glioblastoma's ...

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.